5:21 PM
 | 
Feb 10, 2010
 |  BC Extra  |  Company News

Biovail in-licenses AZ-004

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) granted Biovail Corp. (TSX:BVF; NYSE:BVF) exclusive rights in the U.S. and Canada to develop and commercialize Staccato loxapine ( AZ-004). In December, Alexza submitted an NDA to FDA for AZ-004...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >